Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.
NCT00743652
Completed
This study is to evaluate the safety, immunogenicity and impact of 13-valent Pneumococcal conjugate vaccine in Alaskan Native Children.
Gender:
ALL
Ages:
Between 42 days and 5 years
Trial Updated:
03/13/2012
Locations: Pfizer Investigational Site, Akiak, Alaska +20 locations
Conditions: Pneumococcal Disease, 13-valent Pneumococcal Vaccine
Register for Updates
Pilot Study to Determine the Safety and Efficacy of Gardasil Against the Human Papilloma Virus (HPV) in HIV-infected Men
NCT00666107
Unknown
This study will investigate the efficacy and safety of the quadrivalent vaccine (Gardasil) against the human papilloma virus (HPV) in HIV (human immunodeficiency virus) infected males.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/12/2012
Locations: VA Long Beach Healthcare System, Long Beach, California
Conditions: Anal Cancer, HIV Infections
Register for Updates
Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine
NCT01290419
Completed
A Phase 1, Randomized, Placebo-Controlled, Observer-Blinded, Escalating Dose-Ranging Study to Assess the Safety, and immunogenicity of 6 different recombinant RSV-F formulations in healthy adults (18 to 49 years of age). Study Objectives: Primary: * To assess and compare the safety, reactogenicity, and tolerability of 6 RSV-F protein particle vaccine formulations. Secondary: * To assess and compare the immunogenicity (neutralizing antibody and total anti-F antibody) of the 6 RSV-F protein p... Read More
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
03/06/2012
Locations: Healthcare Discoveries d/b/a ICON Development Solutions, San Antonio, Texas
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™
NCT00772928
Completed
This study is designed to evaluate in a controlled manner the effect of Prevnar® on the immune responses of Pentacel™ Primary Objective - Stage I: To compare the immune responses elicited by an infant series of Pentacel™ when given at different times from or concurrently with a Pneumococcal conjugate vaccine (Prevnar®). Primary Objective - Stage II: To compare the immune responses elicited by a 4th dose of Pentacel™ when given at different times from or concurrently with Prevnar®.
Gender:
ALL
Ages:
Between 42 days and 89 days
Trial Updated:
01/30/2012
Locations: Not set, Montgomery, Alabama +22 locations
Conditions: Diphtheria, Tetanus, Haemophilus Infection, Pertussis, Polio
Register for Updates
Safety Study of Recombinant M2e Influenza-A Vaccine in Healthy Adults
NCT00819013
Completed
This multi-center study will be conducted in the United States with up to 80 healthy adult subjects. Subjects will be scheduled to receive a total of two (2) injections with 1 injection each administered. Subjects will be randomized according to a randomization scheme.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
01/16/2012
Locations: Miami Research Associates, Miami, Florida +2 locations
Conditions: Influenza
Register for Updates
Title: Recombinant Plague Vaccine rF1V in Healthy Volunteers
NCT00332956
Completed
This Phase 2(a) clinical trial is designed as a dose-blinded, block-randomized, multi-center study to select a dosage and schedule of rF1V vaccine for further studies based on the immune response up to Day 210. Additional immunogenicity and safety/reactogenicity data will be collected through Day 540. Selection of dosage and schedule will be based on GMCs and seroconversion rates for anti-F1, anti-V and anti-rF1V antibody titers. Approximately 400 healthy adult volunteers will be enrolled (100 p... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
11/28/2011
Locations: Alta Clinical Research, LLC, Tucson, Arizona +8 locations
Conditions: Healthy Volunteers
Register for Updates
Double Blind, Safety and Immunogenicity Study of Recombinant Botulinum Vaccine A/B
NCT00764634
Completed
This Phase 2 study is a double blind, placebo-controlled, randomized, multicenter investigation of rBV A/B-40 vaccine or placebo in healthy adults, using two different three-dose dosing schedules.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
11/28/2011
Locations: Miami Research Associates, Miami, Florida +5 locations
Conditions: Botulism Vaccine
Register for Updates
Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children
NCT00391391
Completed
Primary Objective: To evaluate for each influenza strain the non-inferiority of Investigational Fluzone vaccine to the standard Fluzone® vaccine in healthy subjects aged 6 to 35 months or 3 to 8 years. Secondary Objectives: * To describe the immunogenicity of of Investigational Fluzone vaccine to the standard Fluzone® vaccine in healthy subjects aged 6 to 35 months or 3 to 8 years. * To describe the safety of of Investigational Fluzone vaccine to the standard Fluzone® vaccine in healthy subje... Read More
Gender:
ALL
Ages:
Between 6 months and 8 years
Trial Updated:
11/21/2011
Locations: Not set, Harrisburg, Arkansas +18 locations
Conditions: Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Register for Updates
Pentavalent DTaP-Hep B-IPV
NCT00133445
Completed
The purpose of this study is to evaluate the safety of administering a combination vaccine (DTaP-HepB-IPV; Pediarix™) to infants at birth, 2 and 6 months compared to the administration of a HepB vaccine at birth and the same combination vaccine at 2, 4, and 6 months of age. Additionally, researchers will assess the body's antibody response (proteins produced by the body's immune system that help fight infections) following each vaccine dose. The study will enroll 5 healthy newborns, ages 0-5 day... Read More
Gender:
ALL
Ages:
5 days and below
Trial Updated:
11/03/2011
Locations: UCLA Center For Vaccine Research, Torrance, California
Conditions: Diphtheria, Hepatitis B, Poliomyelitis, Pertussis, Tetanus
Register for Updates
Recombinant Attenuated Salmonella Typhi Vaccine Vectors Producing Streptococcus Pneumoniae PspA
NCT01033409
Completed
In this Phase I clinical study, three recombinant, avirulent Salmonella Typhi (RASV) strains each expressing the Streptococcus pneumoniae surface protein, PspA, will be compared as live biological vaccine vectors to evaluate safe and tolerable, single, oral dose levels in adult subjects.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
11/01/2011
Locations: Saint Louis University Center for Vaccine Development, St. Louis, Missouri
Conditions: Pneumonia
Register for Updates
Study Evaluating Prevnar Infant Long-term Immune Response Versus Prevnar Naive Cohort
NCT00824850
Completed
The purpose of this study is to assess the "late" immune response to further doses of pneumococcal conjugate vaccine more than 10 years after primary immunization with Prevnar (7vPnC) in infancy, as compared with individuals who did not receive Prevnar in infancy (the Prevnar naive cohort which received MnCC). The study will take place at a single study center. Study participants must have participated previously in a specific Wyeth Prevnar study (Study D118-P8) and must still be enrolled in the... Read More
Gender:
ALL
Ages:
Between 8 years and 16 years
Trial Updated:
10/05/2011
Locations: Pfizer Investigational Site, Hayward, California +1 locations
Conditions: Pneumococcal Conjugate Vaccine
Register for Updates
Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma
NCT00002748
Completed
RATIONALE: Inserting the gene for interleukin-2 into a person's neuroblastoma cells may make the body build an immune response and kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of using interleukin-2 gene-modified neuroblastoma cells in treating children who have refractory or recurrent neuroblastoma.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
10/03/2011
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Neuroblastoma
Register for Updates